Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | NPY2R | P49146 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24637652 | 0.86 | GAA (0.46) | MGLLGAAALOX15KMT2ASMN1; SMN2 | |
| SCHEMBL11882343 | 0.85 | MGLL (0.72) | MGLLGAAALOX15KMT2ASMN1; SMN2 | |
| SCHEMBL27906266 | 0.80 | TSHR (0.57) | GAAKMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL2867370 | 0.80 | GPR119 (0.53) | KMT2ASMN1; SMN2MEN1LMNAMAPK1 | |
| SCHEMBL27780514 | 0.80 | MGLL (0.66) | MGLLGAAALOX15KMT2ASMN1; SMN2 | |
| SCHEMBL955395 | 0.80 | SMN1; SMN2 (0.40) | KMT2ASMN1; SMN2MEN1LMNAMAPK1 | |
| SCHEMBL1578826 | 0.78 | ALDH1A1 (0.78) | MGLLGAAALOX15KMT2ASMN1; SMN2 | |
| SCHEMBL3077817 | 0.78 | SMN1; SMN2 (0.72) | MGLLGAAALOX15KMT2ASMN1; SMN2 | |
| SCHEMBL20324400 | 0.78 | LMNA (0.42) | GAAKMT2ASMN1; SMN2MEN1NPC1 | |
| SCHEMBL7666262 | 0.77 | SMN1; SMN2 (0.41) | KMT2ASMN1; SMN2MEN1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381216-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230381216-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-11642364-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11642364-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20230045831-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | SAREPTA THERAPEUTICS, INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-11491238-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-11384105-B2 | Processes for preparing oligomers | SAREPTA THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11382981-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11338041-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20220017901-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2022-01-20 | — | — | US | disclosed |
| US-20190276480-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-09-12 | — | — | US | disclosed |
| US-20190262375-A1 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| WO-2019059973-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2019-03-28 | — | — | WO | disclosed |
| US-20180177814-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-06-28 | — | — | US | disclosed |
| US-20180177814-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-06-28 | — | — | US | disclosed |
| WO-2017205879-A2 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | SAREPTA THERAPEUTICS, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017205513-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | SAREPTA THERAPEUTICS, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017205496-A1 | PROCESSES FOR PREPARING OLIGOMERS | SAREPTA THERAPEUTICS, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017205880-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | SAREPTA THERAPEUTICS, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20160040162-A1 | EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11338041-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SMN1; SMN2, UTRN, RBM17 | MGLL 4687/4885GAA 725/4885ALOX15 3056/4885 |
| US-20230045831-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | PPIP5K2, MTAP, RNGTT | MGLL 2399/4885GAA 2750/4885ALOX15 1724/4885 |
| US-11382981-B2 | Exon skipping oligomer conjugates for muscular dystrophy | UTRN, SMN1; SMN2, RBM17 | MGLL 4670/4885GAA 736/4885ALOX15 2773/4885 |
| US-11642364-B2 | Exon skipping oligomer conjugates for muscular dystrophy | UTRN, SMN1; SMN2, DCLRE1B | MGLL 4660/4885GAA 741/4885ALOX15 2955/4885 |
| US-20190276480-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | PPIP5K2, MTAP, RNGTT | MGLL 2399/4885GAA 2750/4885ALOX15 1724/4885 |
| US-20220017901-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SMN1; SMN2, MTPN, UTRN | MGLL 4742/4885GAA 818/4885ALOX15 3990/4885 |
| US-11491238-B2 | Exon skipping oligomer conjugates for muscular dystrophy | UTRN, SMN1; SMN2, RBM17 | MGLL 4703/4885GAA 799/4885ALOX15 2966/4885 |
| US-20230381216-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | UTRN, SMN1; SMN2, DCLRE1B | MGLL 4660/4885GAA 741/4885ALOX15 2955/4885 |
| US-20180177814-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | UTRN, SMN1; SMN2, DCLRE1B | MGLL 4660/4885GAA 741/4885ALOX15 2955/4885 |
| US-20190262375-A1 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY | RBM17, UTRN, UPF1 | MGLL 4645/4885GAA 1827/4885ALOX15 2938/4885 |
| US-11384105-B2 | Processes for preparing oligomers | NOP2, RNGTT, PCBP1 | MGLL 2490/4885GAA 2165/4885ALOX15 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.